X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6698) 6698
Publication (824) 824
Newsletter (689) 689
Newspaper Article (367) 367
Book Review (281) 281
Book / eBook (99) 99
Book Chapter (89) 89
Magazine Article (45) 45
Trade Publication Article (45) 45
Dissertation (23) 23
Conference Proceeding (21) 21
Report (16) 16
Transcript (5) 5
Data Set (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4929) 4929
hiv (3137) 3137
hiv infections - drug therapy (3057) 3057
index medicus (2691) 2691
pharmacology & pharmacy (2254) 2254
male (2246) 2246
female (2116) 2116
protease inhibitors (1875) 1875
human immunodeficiency virus--hiv (1827) 1827
adult (1816) 1816
infectious diseases (1801) 1801
drug therapy (1625) 1625
pharmacokinetics (1540) 1540
antiviral agents (1495) 1495
aids (1353) 1353
hiv protease inhibitors - pharmacokinetics (1270) 1270
antiretroviral therapy (1224) 1224
middle aged (1219) 1219
hiv infection (1216) 1216
anti-hiv agents - therapeutic use (1187) 1187
drug interactions (1137) 1137
antiretroviral drugs (1135) 1135
research (1069) 1069
ritonavir (1048) 1048
drug therapy, combination (984) 984
immunology (961) 961
hiv protease inhibitors - therapeutic use (899) 899
animals (885) 885
virology (883) 883
hiv-1 - drug effects (880) 880
human-immunodeficiency-virus (844) 844
highly active antiretroviral therapy (838) 838
hiv infections - virology (824) 824
health aspects (823) 823
anti-hiv agents - pharmacokinetics (791) 791
microbiology (787) 787
therapy (697) 697
hiv protease inhibitors - administration & dosage (683) 683
human immunodeficiency virus (678) 678
viral load (664) 664
anti-hiv agents - administration & dosage (658) 658
proteases (658) 658
treatment outcome (636) 636
acquired immune deficiency syndrome--aids (621) 621
care and treatment (619) 619
hiv-1 (582) 582
drugs (574) 574
infection (568) 568
pharmacology (567) 567
ritonavir - pharmacokinetics (564) 564
dosage and administration (551) 551
hiv patients (535) 535
hiv protease inhibitors - pharmacology (533) 533
ritonavir - administration & dosage (531) 531
lopinavir (526) 526
anti-hiv agents (518) 518
anti-hiv agents - adverse effects (517) 517
ritonavir - therapeutic use (517) 517
virus diseases (510) 510
drug resistance (497) 497
antiretroviral therapy, highly active (489) 489
infections (486) 486
anti-hiv agents - pharmacology (481) 481
hiv infections - complications (481) 481
hiv protease inhibitors - adverse effects (471) 471
clinical trials (468) 468
medicine (462) 462
research article (456) 456
analysis (446) 446
indinavir (444) 444
reverse transcriptase inhibitors - therapeutic use (444) 444
cd4 lymphocyte count (442) 442
protease inhibitor (437) 437
adolescent (436) 436
risk factors (416) 416
area under curve (415) 415
active antiretroviral therapy (414) 414
in-vitro (413) 413
medical research (409) 409
hiv-infected patients (407) 407
p-glycoprotein (407) 407
hiv protease inhibitors - blood (405) 405
viruses (395) 395
aids/hiv (388) 388
safety (381) 381
saquinavir (374) 374
hiv infections - metabolism (373) 373
drug administration schedule (372) 372
drug resistance, viral (370) 370
efavirenz (364) 364
tenofovir (363) 363
pregnancy (361) 361
patients (354) 354
metabolism (348) 348
resistance (347) 347
dose-response relationship, drug (345) 345
efficacy (343) 343
hiv-1 - genetics (342) 342
young adult (335) 335
article (332) 332
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (77) 77
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Credit Valley Hospital - Stacks (3) 3
Online Resources - Online (3) 3
St. Michael's Hospital - Stacks (3) 3
Toronto East General Hospital - Stacks (3) 3
Humber River Regional Hospital - Church Stacks (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
New College (Ivey) - Stacks (2) 2
Providence Healthcare - Reference (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Credit Valley Hospital - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Reference (1) 1
Law (Bora Laskin) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7926) 7926
Spanish (67) 67
French (28) 28
German (18) 18
Japanese (12) 12
Russian (4) 4
Portuguese (3) 3
Italian (2) 2
Chinese (1) 1
Croatian (1) 1
Dutch (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2011, Volume 55, Issue 7, pp. 3517 - 3521
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
MICROBIOLOGY | PHARMACOLOGY & PHARMACY | RALTEGRAVIR | HEALTHY-SUBJECTS | AMPRENAVIR | Young Adult | Drug Interactions | Ritonavir - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Adult | Male | Pyridazines - pharmacokinetics | HIV Integrase Inhibitors - pharmacokinetics | Pharmacology
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
Background & Aims BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | PLUS RIBAVIRIN | BILN-2061 | TELAPREVIR | EFFICACY | VX-950 | HEPATITIS-C-VIRUS | IN-VITRO | EARLY ANTIVIRAL ACTIVITY | PEGINTERFERON ALPHA-2A | ATAZANAVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 8, pp. 972 - 979
Background. Guidelines for the treatment of human immunodeficiency virus (HIV) infection consistently recommend initiation of antiretroviral therapy in... 
pharmacokinetics | direct-acting antiviral HCV drugs | HIV | hepatitis C | HIV protease inhibitors | INFECTIOUS DISEASES | ABT-450/R-OMBITASVIR | MICROBIOLOGY | RIBAVIRIN | IMMUNOLOGY | THERAPY | HCV | RITONAVIR | Anilides - therapeutic use | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Healthy Volunteers | Carbamates - pharmacokinetics | Young Adult | Drug Therapy, Combination - adverse effects | Drug Interactions | Uracil - administration & dosage | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Hepatitis C - complications | HIV Protease Inhibitors - adverse effects | Hepacivirus - drug effects | Drug Administration Schedule | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Macrocyclic Compounds - pharmacokinetics | Uracil - therapeutic use | HIV Protease Inhibitors - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Coinfection - virology | Sulfonamides - pharmacokinetics | Macrocyclic Compounds - therapeutic use | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Sulfonamides - therapeutic use | Adolescent | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Research | Hepatitis C virus | HIV (Viruses) | Patients | Health aspects | Methods | Antiretroviral drugs | Hepatitis | Protease inhibitors | Human immunodeficiency virus--HIV | Medical treatment
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Non-blinded, single center, open-label pharmacokinetic study... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 07/2005, Volume 56, Issue 1, pp. 1 - 5
The HIV-1 protease inhibitors (PIs) are widely used in combination antiretroviral therapy for the management of HIV-1 infection. Certain characteristics of the... 
Antiretroviral | Drug-drug interactions | HIV therapy | antiretroviral | INFECTIOUS DISEASES | drug-drug interactions | THERAPY | VOLUNTEERS | DRUGS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | RITONAVIR
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2014, Volume 54, Issue 8, pp. 949 - 957
This study compared the bioavailability of two candidate fixed-dose combinations (FDCsG003 and G004) of darunavir/cobicistat 800/150 mg with that of darunavir... 
fixed‐dose combination | darunavir | cobicistat | bioavailability | pharmacoenhancer | fixed-dose combination | EFFICACY | SAFETY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | PROTEASE INHIBITORS | TREATMENT-NAIVE | HIV | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | ONCE-DAILY DARUNAVIR/RITONAVIR | Thiazoles - blood | Darunavir | Humans | Middle Aged | Biological Availability | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Young Adult | Sulfonamides - blood | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ritonavir - administration & dosage | Ritonavir - blood | Carbamates - blood | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Cross-Over Studies | Ritonavir - pharmacokinetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cobicistat | Drug Combinations | Sulfonamides - administration & dosage | Usage | Dosage and administration | Drug therapy, Combination | Pharmacokinetics | Analysis | Short term
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2013, Volume 56, Issue 2, pp. 300 - 306
Journal Article